TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07805356: Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism

Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 160 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$8,014,480

Rescue Site Savings

+$5,280,128

Unlock Full NCT07805356 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07805356 Rescue Dossier →